Loading…
Biotech Next Gen 2021 has ended
avatar for Eric Rubin, M.D.

Eric Rubin, M.D.

Merck Research Labs
SVP & Therapeutic Area Head, Oncology Early Development

 Dr. Rubin has focused on cancer drug development for over 25 years, initially as a faculty member at the Dana-Farber Cancer Institute, then as a senior leader of the Cancer Institute of New Jersey, where he served as the Director of the Investigational Therapeutics Division of that institution. His research efforts focused on mechanisms of resistance to DNA topoisomerase-targeting drugs and his laboratory cloned TOPORS, a novel topoisomerase I- and p53-interacting tumor suppressor gene. In 2008 he was recruited to Merck to lead the clinical oncology development team. Under his leadership, the clinical oncology group underwent a transformational change in an effort to realize the potential of cancer immunotherapy. He led the initial development of the anti-PD-1 antibody pembrolizumab, which was the first anti-PD-1 therapy approved in the U.S., and in the identification of the significant activity of this breakthrough therapeutic across several cancertypes. In 2014 Dr. Rubin was asked to head up Oncology Early Development for Merck, and in this role heoversees development of a promising and expansive early pipeline, as well as translational oncology researchactivities.

My Speakers Sessions

Tuesday, June 22
 

1:00pm EDT